Table of Contents
<< Previous Issue | Mar 2018 (Vol: 2018, Issue: 3) | Next Issue >> |
- Section: Opinion & Analysis
-
Pharma Deals: Review of 2017
- Section: Research & Development
-
Takeda and Wave Partner to Develop Stereopure Nucleic Acid Therapies for CNS Disorders
-
AbbVie Investigates One-Dose Therapy for Alzheimer’s with Voyager Therapeutics Collaboration
-
Merck & Co. Signs Multibillion-Dollar Deal with Eisai for Lenvima®
-
Celgene Collaborates with Vividion for US$101 M Upfront to Target Tough-to-Drug Proteins
- Section: Technology Access
-
Gilead’s Kite Signs US$3.15 B Genome Editing Deal with Sangamo